Andrew Davies joins ABHI
This article was originally published in Clinica
Executive Summary
Forearming for the commercial access battles ahead, the UK medical devices industry association, ABHI, has appointed Andrew Davies as director of market access. Mr Davies, who has worked within the medical technology divisions of Thorn EMI, Philips and Bristol-Myers Squibb, has responsibility for ensuring that UK reimbursement structures are appropriate to the current evaluation and adoption models for medical devices. The maintenance of efficient access and payment structures requires ongoing dialogue between industry and policy makers, in which task the new ABHI director can bring to bear 20 years of medical devices industry experience, including roles in UK and international marketing and business development in the capital and consumable equipment sectors. The ABHI has also appointed senior registrar in anaesthetics Dr William Wynn-Jones as clinical fellow for one year, in which role he will help build relationships between NHS clinicians and the medical technologies industry as regards working within the NHS Outcomes Framework.
You may also be interested in...
The Sustainability Stakes Are Rising: ‘We Cannot Recycle Our Way Out Of This’
The journey to Net Zero, described as ‘the defining issue of our time,’ will get harder in the coming decade. Failure to keep up the pressure will result in more long-term health conditions, increasing deaths and higher costs. The UK NHS is a Net Zero exemplar globally, but without a systemic approach, its compliance efforts could stutter.
UK Life Sciences Cautiously Upbeat For Investment Year Ahead – BioWales 2024
Favorable UK biopharma investment trends have been reported by the BioIndustry Association, but can medtech and healthtech share in the positivity? A roundtable at the BioWales in London 2024 event framed the outlook for non-pharma players.
An Ecosystem For Medtech Funding And Innovation Support – BioWales 2024
Creo Medical and Clinithink are among the healthtech innovators who have benefited from funding and advisory support offered by the Development Bank of Wales. All three gave a take on the current funding environment at BioWales in London 2024.